Navigation Links
New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
Date:9/18/2007

More than 10 data presentations demonstrate the safety and activity of

MYCAMINE as an antifungal agent

CHICAGO, Sept. 18 /PRNewswire/ -- New data from a pooled analysis of 17 clinical studies demonstrate that MYCAMINE(R) (micafungin sodium) for injection offers a favorable clinical safety profile in hospitalized patients of all ages with serious, underlying diseases with immunosuppressed status. These studies, which represent the largest published safety data for an antifungal medicine to date, looked at more than 3,000 patients who received at least one dose of MYCAMINE, with median treatment lasting 18 days. Importantly, the investigators attribute few adverse events to treatments, even in longer periods of exposure. Comparative study data showed MYCAMINE had a similar safety profile to fluconazole, caspofungin and liposomal amphotericin B. These data were presented today at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

MYCAMINE is approved for the treatment of patients with esophageal candidiasis and is the only echinocandin approved for the prophylaxis of Candida infections and in patients undergoing hematopoietic stem cell transplantation.

"While current therapies may adequately treat many patients, drug safety is particularly critical in certain populations, particularly elderly patients," said Oliver Cornely, MD, University Hospital of Cologne, Germany. "These findings should be reassuring to physicians, in that they shed light on the safety and tolerability of MYCAMINE which has been studied more than any other echinocandin."

In addition to this analysis, 11 other MYCAMINE abstracts were accepted for presentation at this year's ICAAC meeting. When looked at together, the data provide further insight on MYCAMINE and its activity, demonstrating its value as an effective treatment for invasive fungal infections, compared to other drugs in its class.

"Astella
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Urinalysis Analyzers: Large Capabilities in Every Size Device
2. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
5. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
6. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
7. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
8. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
9. Large Study Shows that Presence of Neutralizing Antibodies Did Not Predict Clinical Response to Betaseron Treatment
10. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
11. Managing Preanalytical Processes for Patient Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...TON, Calif., Oct. 10 /- TriReme Medic...horized to affix the CE (Conformite,Europeenne) ma...Coronary,Stent System, a unique main vessel stent ...ary bifurcations., Representing the next generati... has potential use in a quarter of the 2.2 million...
(Date:10/9/2008)...ight Day 2008 focuses on the need to protect the e...wire/ -- Of the 45 million people worldwide who,ar...rters of them could,have avoided their blindness i...o view the Multimedia News Release, go to:, http:/... world,s leader in eye care products and equipment...
(Date:10/9/2008)...e Clinical Results Expected in November 2008, BOT...R Pharma, Inc.,(Amex: DDD ) announced today the c... third of its three pivotal trials to evaluate the... extended-release (ER) ibuprofen for,the over-the-...t top-line,results from this pivotal trial in Nove...
(Date:10/9/2008)...LM, October 9 /- Diamyd Med...ical journal, the New England Journal,of Medicine,...mpany,s study,of the Diamyd(R) diabetes vaccine fo...m/cgi-bin/prnh/20080314/297194 ), The article is...www.nejm.org ) and will be in print on October 30....
Breaking Medicine Technology:TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2ORBIS and Alcon Call Attention to the Aging Eye 2ORBIS and Alcon Call Attention to the Aging Eye 3SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3Diamyd(R) Study Published in Prestigious New England Journal of Medicine 2Diamyd(R) Study Published in Prestigious New England Journal of Medicine 3Diamyd(R) Study Published in Prestigious New England Journal of Medicine 4Poverty Drains Nutrition From Family Diet 12398 1Poverty Drains Nutrition From Family Diet 12398 2Poverty Drains Nutrition From Family Diet 12398 3First Lady Laura Bush Visits AED Netmark Malaria Control Project in Ghana 12394 1First Lady Laura Bush Visits AED Netmark Malaria Control Project in Ghana 12394 2Yoga Journal Circulation Increases 5 8 Percent in Second Half of 2007 from Same Period Previous Year 12390 1Yoga Journal Circulation Increases 5 8 Percent in Second Half of 2007 from Same Period Previous Year 12390 2Emageon Reports Fourth Quarter and 2007 Financial Results 12386 1Emageon Reports Fourth Quarter and 2007 Financial Results 12386 2Emageon Reports Fourth Quarter and 2007 Financial Results 12386 3Emageon Reports Fourth Quarter and 2007 Financial Results 12386 4Emageon Reports Fourth Quarter and 2007 Financial Results 12386 5Emageon Reports Fourth Quarter and 2007 Financial Results 12386 6Emageon Reports Fourth Quarter and 2007 Financial Results 12386 7Emageon Reports Fourth Quarter and 2007 Financial Results 12386 8Emageon Reports Fourth Quarter and 2007 Financial Results 12386 9
...07-AstraZeneca today announced clinical,trial data...apine,fumarate sustained release), at the European...demonstrated that the SEROQUEL®,sustained rele...ease), administered once daily, significantly impr...red by PANSS) and increased the,time to psychiatri...
...S WIRE)--Mar 20, 2007 - MGI PHARMA, INC.,(NASDAQ: ...logy and,acute care, today announced that a random...trial of Aquavan(R) (fospropofol,disodium) Injecti...y successfully met its primary endpoint of sedatio...g patients who,received an initial bolus dose of 6...
Other Medicine Technology:Seroquel Sustained Release Schizophrenia Data Presented at ECP,Congress in Madrid 2Seroquel Sustained Release Schizophrenia Data Presented at ECP,Congress in Madrid 3Seroquel Sustained Release Schizophrenia Data Presented at ECP,Congress in Madrid 4MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy 2MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy 3MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy 4MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy 5MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy 6
(Date:10/10/2008)...Coach Holly Warlick Teams Up with Legal and Medica...Ever Cancer and Careers Seminar in,Knoxville, KNO...ion of National,Breast Cancer Awareness Month, Can...e joined forces with YWCA Knoxville, The Wellness ...e Holly Warlick, University of Tennessee,women,s b...
(Date:10/10/2008)... The Healthcare Technology Ev... , Exton, PA (PRWEB) Sept...ey Chapters of the national Healthcare Information...forces to bring regional health information techno... conference entitled The Healthcare Technology Evo...
(Date:10/10/2008)...ston, MABoston Medical Center (BMC) has received a...l Institute on Aging (NIA) to fund the Boston Clau...BMC,s Pepper Center is one of only 11 Pepper Cente... Americans Independence Center Program was establi...enator from Florida. During his five decades of pu...
(Date:10/10/2008)...olecular CT adds metabolic information from PET to...gnostic imaging for maximized workflow ...ICH, Germany, Oct. 10 /PRNewswire/ -- Siemens Heal...duces molecular CT, a new concept in,integrated im...d is a,practical solution for today,s shrinking he...
Breaking Medicine News(10 mins):Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2Health News:Boston Medical Center receives $5.8m grant 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 3Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 4
...fare, Indian scientists have been sequencing the g...It is India's first sequencing effort of a complet...several diseases, including tuberculosis and lepro...de from killed Mw drastically reduces treatment ti...
...fer from migraine are more at risk of heart attack...ological condition, of which the most common sympt... Men with migraines were more likely to have high...d cholesterol levels, compared to men who didn't h...
...a bacterium, which is one of the leading cause for...ing cause for blindness globally, is said to be// ...ve imagined. The scientists from Children’s Hospi...ere the first to conclude this with the help of a ...
...two important changes that revolve around prematur...ch-greater ability of medical advances to keep// a...nge that has been noted is the increased rate of p...e births resulting from fertility treatment. A re...
Other Medicine News:Health News:India Finds New Use for an Old Bug 2Health News:India Finds New Use for an Old Bug 3Health News:Newly Identified Strains Of Chlamydia Trachomatis – A Gateway To New Disease 2Health News:Premature Babies- What should be done about them? 2
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
Medicine Products: